ILMNIllumina Inc
Company Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Tags
Dividends
No dividend
Sentiment
Score
Bullish
78
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Interest Expense
Interest & Investment Income
Other Income / (Expense), net
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/ACompany Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Tags
Dividends
No dividend
Sentiment
Score
Bullish
78
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Interest Expense
Interest & Investment Income
Other Income / (Expense), net
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/AUpcoming Earnings
Company Info
CEO
Francis A. deSouza
Location
California, USA
Exchange
Nasdaq
Website
https://illumina.com
Summary
Illumina, Inc.
Company Info
CEO
Francis A. deSouza
Location
California, USA
Exchange
Nasdaq
Website
https://illumina.com
Summary
Illumina, Inc.
Community Research
Research from investors like you
Be the first to share your analysis on ILMN
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.
Symbol's posts
Biopharma Demand Is Growing, and Genomics Could Be a Key Beneficiary
Biopharma Demand Is Growing, and Genomics Could Be a Key Beneficiary
One area I’m keeping an eye on is next-generation sequencing, especially as biopharma companies look for better ways to develop targeted treatments and understand complex diseases. Illumina remains an important name in sequencing technology, while Thermo Fisher Scientific offers broader tools and services to research labs and drug developers.
What interests me is whether strong demand can translate into consistent revenue growth and better profitability. The long-term opportunity looks promising, but competition, research budgets, and spending cycles still matter. I’d rather focus on companies that can turn scientific progress into sustainable business results.
Do you see genomics as a long-term growth opportunity, or is the sector still too uncertain to invest in confidently?
Three companies just got an S&P 500 upgrade
Three companies just got an S&P 500 upgrade
, and Everpure are set to join the S&P 500 later this month. jumped about 5.3% after the announcement and is already up roughly 20% over the past week. Being included in an index definitely has a crazy effect on stocks.
it's Biotechin time
it's Biotechin time

stocknews.com
| ILMN: 3 B-Rated Biotech Stocks to Boost Your Bottom Line | StockNews.com
No more topics to show
